



What's New

03.01.2017

Re-Constitution of Committee of Expert under Drugs (Price Control) Order, 2013 to recommend fixation of separate ceiling/retail price of formulation which fall under the purview of Para 11(3&4) of DPCO 2013.

The fourth meeting of the committee of Experts constituted under para 11(3&4) of DPCO, 2013 is scheduled to be held on 18.01.2017(Wednesday) at 11.00 AM to consider the cases as on date (Annexure) under the provision contained in Para 11(3 & 4) of DPCO, 2013.

Para 11(3 & 4) of DPCO, 2013 states that:

- (a) Notwithstanding anything contained in sub-paragraphs (1) and (2), in case of injections or inhalation or any other medicine for which dosages from or strength or both are not specified in the Drugs (Prices Control) Order, 2013, the Government may fix and notify separate ceiling price or retail price for such formulations with specific therapeutic rationale, considering the type of packaging or pack size or dosage compliance or content in the pack namely liquid, gaseous or any other from, in the unit dosage as the case may be, conforming to Indian Pharmacopeia or other standards as specified in the Drugs and Cosmetics Act, 1940 (23 of 1940) and the rules made thereunder for the same formulation.

- (b) The Government shall form a Committee of Expert, as it may deem fit, within a period of fifteen days from the date of issue of this order, to recommend fixing of separate ceiling price of scheduled formulation or retail price of a new drugs as per the above parameters.

NPPA has reconstituted the Committee of Experts under Para 11(3 & 4) of DPCO 2013 as under:

1	Adviser (cost), National Pharmaceuticals Pricing Authority	Chairperson
2	Representative of Drug Controller general of India Ministry of Health and Family Welfare, New Delhi	Member
3	The Head of Department of Cardiology, AIIMS, New Delhi or representative	Member
4	The Head of Department of Medicine, AIIMS, New Delhi or representative	Member
5	Prof. Y.K Gupta, Head Department of Pharmacology,	Member

	AIIMS, New Delhi or representative	
6	The Executive Director, National Health System resource Centre or representative	Member
7	Dr. Sarita Dhawan, Add. Director/director, CGHS, New Delhi or representative	Member
8	Director, Delhi Institute of Pharmaceuticals Science and Research (DIPSR) or representative	Member
9	Shri. D. P. Pathak, Director/Director, Indian Council of Medical Research or representative	Member
10	Any other subject specialist/expert co-opted by the committee on case to case basis	Member
11	Director (Pricing),NPPA	Convener

The committee shall recommend fixing of separate ceiling price of scheduled formulation or retail price of new drug as per the parameters mentioned under para 11 (3 & 4) of DPCO 2013.

Annexure

Cases as on date 03.01.2016 - Representation of companies under para 11(3)

Sr. No.	Company Name	Formulation	S.O. No.	Dated	Received on
1	Cipla	Budesonide Inhalation 100 mcg & 200 mcg	1561(E)	27.4.2016	12.7.2016 & 25.11.2016
2	Unimed	Pre – Filled syringe and Glass Vial packs of Hydroxypropyl Methylcellulose injection 2%	1561(E)	27.4.2016	11.8.2016
3	Aurolab	Hydroxypropyl Methylcellulose injection 1%	1561(E)	27.4.2016	30.8.2016
4	Ipca	Metoclopramide injection 2 ml Ampoul and 10ml vial each containing 5mg/ ml	3431(E)		
5	Wockhadt	Dicyclomine injection		10.11.2016	24.11.2016
6	Glenmark	Digihaler FB 100/200/400 and Budesonide/ Formoterol (100/6, 200/6 and 400/6 mcg)			15.12.2016
7	Abbott	Tramadol injection 50mg/ml			
8	IDMA	Small volume Parenterals			

["Meeting of the committee of Experts under para 11\(3 & 4\) of DPCO on 18.01.2017\(Wednesday\) at 11.00 AM."](#)